[go: up one dir, main page]

PE20120543A1 - Anticuerpo anti-tau ps422 - Google Patents

Anticuerpo anti-tau ps422

Info

Publication number
PE20120543A1
PE20120543A1 PE2011002053A PE2011002053A PE20120543A1 PE 20120543 A1 PE20120543 A1 PE 20120543A1 PE 2011002053 A PE2011002053 A PE 2011002053A PE 2011002053 A PE2011002053 A PE 2011002053A PE 20120543 A1 PE20120543 A1 PE 20120543A1
Authority
PE
Peru
Prior art keywords
tau
phosphorilated
seq
antibody
disease
Prior art date
Application number
PE2011002053A
Other languages
English (en)
Inventor
Bernd Bohrmann
Ulrich Goepfert
Fiona Grueninger
Walter Huber
Valeria Lifke
Olaf Mundigl
Sonja Offner
Laurence Ozmen
Michael Schraeml
Hans-Willi Krell
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20120543A1 publication Critical patent/PE20120543A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN ANTICUERPO QUE SE UNE A LA TAU FOSFORILADA EN LA SERINA 422 (TAU PS422) QUE SE UNE ESPECIFICAMENTE AL FRAGMENTO TAU FOSFORILADO DE LA SEQ ID NO:9 Y A LA TAU PS422 PERO QUE NO SE UNE A LA TAU NI AL FRAGMENTO MCAK FOSFORILADO DE LA SEQ ID NO:17, DONDE DICHO ANTICUERPO ES DE LOS SUBTIPOS IgG1 O IgG4. TAMBIEN ESTA REFERIDA A UN ACIDO NUCLEICO Y A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DE TAUOPATIAS TALES COMO LA ENFERMEDAD DE ALZHEIMER, DEMENCIA PUGILISTICA, LA ENFERMEDAD DE PICK, ENTRE OTRAS
PE2011002053A 2009-06-10 2010-06-08 Anticuerpo anti-tau ps422 PE20120543A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30

Publications (1)

Publication Number Publication Date
PE20120543A1 true PE20120543A1 (es) 2012-05-23

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002053A PE20120543A1 (es) 2009-06-10 2010-06-08 Anticuerpo anti-tau ps422

Country Status (22)

Country Link
US (2) US8609097B2 (es)
EP (1) EP2440578B1 (es)
JP (2) JP2012529275A (es)
KR (1) KR101429367B1 (es)
CN (1) CN102459333B (es)
AR (1) AR077016A1 (es)
AU (1) AU2010257799B2 (es)
BR (1) BRPI1012993A2 (es)
CA (1) CA2762594C (es)
CL (1) CL2011003122A1 (es)
CO (1) CO6450613A2 (es)
CR (1) CR20110606A (es)
EC (1) ECSP11011514A (es)
IL (1) IL216509A0 (es)
MA (1) MA33339B1 (es)
MX (1) MX2011012837A (es)
NZ (1) NZ596187A (es)
PE (1) PE20120543A1 (es)
RU (1) RU2536247C2 (es)
SG (1) SG176754A1 (es)
TW (1) TW201103560A (es)
WO (1) WO2010142423A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
DK3345903T3 (da) 2009-06-10 2019-11-11 Chugai Pharmaceutical Co Ltd Tetracykliske forbindelser
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MX347505B (es) 2011-09-19 2017-04-28 Axon Neuroscience Se Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.
HRP20191342T1 (hr) 2011-12-20 2019-11-01 Janssen Biotech Inc Anti-phf-tau antitijela i njihove upotrebe
CN109810188A (zh) 2011-12-21 2019-05-28 弗·哈夫曼-拉罗切有限公司 用于克隆和表达关联抗体可变区基因区段的快速方法
NZ630536A (en) 2012-05-31 2017-03-31 Teijin Pharma Ltd Therapeutic agent or prophylactic agent for dementia
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
RU2729831C2 (ru) 2012-08-24 2020-08-12 Чугаи Сейяку Кабусики Кайся ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
SG11201502211QA (en) 2012-09-25 2015-05-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
WO2014096321A1 (en) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
CN111205368B (zh) * 2012-12-21 2023-05-09 比奥根Ma公司 人抗-tau抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
RS60031B1 (sr) 2013-12-20 2020-04-30 Hoffmann La Roche Humanizovana anti-tau(ps422) antitela i načini upotrebe
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
US9732148B2 (en) * 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
US10160799B2 (en) * 2014-11-19 2018-12-25 Axon Neuroscience Se Humanized tau antibodies in a alzheimer's disease
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
JP6917899B2 (ja) * 2015-04-16 2021-08-11 ハー・ルンドベック・アクチエゼルスカベット 抗ｐａｃａｐ抗体及びそれらの使用
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
EP3313877B1 (en) * 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
KR102770650B1 (ko) * 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
FI3334761T3 (fi) * 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
RU2760875C1 (ru) 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
AU2018221049A1 (en) 2017-02-17 2019-09-19 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EA202091756A1 (ru) 2018-02-01 2020-10-28 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, специфично связывающиеся с тау-белком
US12234280B2 (en) 2018-03-05 2025-02-25 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
CN112567033A (zh) 2018-07-03 2021-03-26 豪夫迈·罗氏有限公司 用于调节Tau表达之寡核苷酸
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
HRP20250284T1 (hr) 2018-09-04 2025-04-25 Chugai Seiyaku Kabushiki Kaisha Postupak dobivanja tetracikličkog spoja
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0618968B1 (en) 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides

Also Published As

Publication number Publication date
JP2017031176A (ja) 2017-02-09
RU2011152816A (ru) 2013-07-20
HK1166331A1 (en) 2012-10-26
US8609097B2 (en) 2013-12-17
NZ596187A (en) 2013-11-29
RU2536247C2 (ru) 2014-12-20
CA2762594A1 (en) 2010-12-16
KR20120024952A (ko) 2012-03-14
JP6513617B2 (ja) 2019-05-15
EP2440578B1 (en) 2017-03-08
IL216509A0 (en) 2012-02-29
CA2762594C (en) 2017-02-28
KR101429367B1 (ko) 2014-08-11
CN102459333B (zh) 2015-07-15
EP2440578A2 (en) 2012-04-18
SG176754A1 (en) 2012-01-30
CN102459333A (zh) 2012-05-16
US9290567B2 (en) 2016-03-22
AR077016A1 (es) 2011-07-27
CO6450613A2 (es) 2012-05-31
BRPI1012993A2 (pt) 2018-01-16
MA33339B1 (fr) 2012-06-01
AU2010257799B2 (en) 2013-10-17
US20130310541A1 (en) 2013-11-21
US20110059093A1 (en) 2011-03-10
JP2012529275A (ja) 2012-11-22
CR20110606A (es) 2012-01-12
WO2010142423A2 (en) 2010-12-16
TW201103560A (en) 2011-02-01
MX2011012837A (es) 2011-12-16
AU2010257799A1 (en) 2011-12-01
CL2011003122A1 (es) 2012-07-20
WO2010142423A3 (en) 2011-05-26
ECSP11011514A (es) 2012-01-31

Similar Documents

Publication Publication Date Title
PE20120543A1 (es) Anticuerpo anti-tau ps422
PE20090726A1 (es) Anticuerpos anti-ige apoptoticos
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
PE20121360A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
NZ597692A (en) Anti-IGF antibodies
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
PE20141162A1 (es) Anticuerpos anti-il-23
GT200600186A (es) Agentes de unión
MX359680B (es) Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores.
EA201290370A1 (ru) Антитела против flt3 и способы их применения
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
BR112012011740A2 (pt) polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
UA111818C2 (uk) Антитіло проти csf-1r
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
EA201490677A1 (ru) Связывающие антиген cd27l белки
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CR10555A (es) Vacunas para malaria
CL2008001887A1 (es) Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
MA34907B1 (fr) Molécules d'anticorps se liant à il-17a et il-17f
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
PH12014502669A1 (en) Therapeutic agent or prophylactic agent for dementia

Legal Events

Date Code Title Description
FC Refusal